# Estrogen Receptor and NFkB Crosstalk in Breast Cancer

> **NIH NIH R01** · UNIVERSITY OF ILLINOIS AT CHICAGO · 2023 · $467,442

## Abstract

More than 230,000 women in the US will be diagnosed with breast cancer and nearly 40,000 will die from the
disease annually. The majority of breast tumors express estrogen receptor α (ER), found in ~70-80% of all cases.
Women with ER+ tumors typically receive endocrine therapy (ET), such as aromatase inhibitors or tamoxifen
(TAM). While initial survival rates are generally good, it is estimated that ~40% of ER+ tumors will relapse, with
almost half of these recurring after completing the standard 5 years of adjuvant ET. This risk for late relapse
suggests that in many cases a population of tumor cells can persist or tolerate ET agents, only to contribute to
relapse once ET is completed. This conclusion is supported by several studies showing that 10 yr of ET is
superior to 5 yr. In studying how early responses to the selective pressure of ET might contribute to ET-tolerance,
we found that activation of NFB was a common event in ER+ breast tumors of patients treated with neo-adjuvant
ET, as well as in ER+ breast cancer cell lines, patient derived organoids, and xenografts. This activation appears
to be the result of an expansion of NFB+ breast cancer cells that can proliferate and persist despite ET
treatment. Importantly, inhibiting NFB prevents relapse, as determined by the lack of regrowth of cells and
tumors once TAM treatment is terminated. Moreover, we found that a gene signature derived from ET-tolerant
cells was associated with high tumor grade and increased risk of relapse in patients with ER+ disease. Based
on these findings, we hypothesize that the selective pressure of ET allows for the expansion of NFB+, ET-
tolerant cell populations and that targeting these populations therapeutically will prevent relapse and disease
progression. To test this, we propose three aims: Aim 1. To define ET-tolerant cell populations in ER+ breast
cancer models; Aim 2. To determine the mechanism of NFB regulation and action in ET-tolerance; and Aim 3.
To investigate the consequences of targeting ET-tolerant cell populations. To address these aims, we will
perform single cell RNA-seq on ET-treatment naïve preclinical models under the selective pressure of short-term
ET and over time as adaptive resistance develops. We will then investigate the persistence of these populations
in preclinical models of ET-resistance and validate our findings in human primary and metastatic tumors. We will
also examine the hypothesis that NFB activity in ET-tolerant cells is a response to cellular stress caused by the
selective pressure of ET, as well as a protective player in response to that cellular stress. In addition, we will use
complementary genetic and small molecule inhibitors that inhibit the NFB pathway, as well as inhibitors of key
NFB regulators and effectors, to test the role of ET-tolerant cells in relapse and disease progression, using both
patient-derived tumors in immunocompromised mice and an immunocompetent mouse model. The successful
completion of ...

## Key facts

- **NIH application ID:** 10558646
- **Project number:** 5R01CA200669-07
- **Recipient organization:** UNIVERSITY OF ILLINOIS AT CHICAGO
- **Principal Investigator:** Jonna Frasor
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $467,442
- **Award type:** 5
- **Project period:** 2015-12-04 → 2027-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10558646

## Citation

> US National Institutes of Health, RePORTER application 10558646, Estrogen Receptor and NFkB Crosstalk in Breast Cancer (5R01CA200669-07). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10558646. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*